Loading...

Paul Aisen, MD

Title(s)Professor of Neurology
AddressATRI 9860 Mesa Rim Road
Health Sciences Campus
San Diego CA 92121
Phone+1 858 964 1411
vCardDownload vCard
    Other Positions
    Title(s)Director, Alzheimer's Therapeutic Research Institute


    Collapse Overview 
    Collapse Overview
    Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

    Collapse Research 
    Collapse Research Activities and Funding
    COG0202, A Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
    NIH R01AG065248Jun 1, 2020 - May 31, 2025
    Role: Co-Principal Investigator
    Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
    NIH R01AG063689May 15, 2019 - Dec 31, 2024
    Role: Co-Principal Investigator
    Combination anti-amyloid therapy for preclinical Alzheimer's disease
    NIH R01AG061848Sep 30, 2018 - May 31, 2025
    Role: Principal Investigator
    API A4 Alzheimer's Prevention Trial
    NIH R01AG058468Sep 1, 2018 - Nov 30, 2024
    Role: Co-Principal Investigator
    Alzheimer's Clinical Trials Consortium (ACTC)
    NIH U24AG057437Dec 2, 2017 - Nov 30, 2022
    Role: Principal Investigator
    Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
    NIH R01AG053798May 1, 2017 - Apr 30, 2023
    Role: Principal Investigator
    The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
    NIH R01AG054029Aug 15, 2016 - Apr 30, 2024
    Role: Co-Principal Investigator
    Long-Term Nicotine Treatment of Mild Cognitive Impairment
    NIH R01AG047992Sep 15, 2015 - May 31, 2021
    Role: Co-Principal Investigator
    Alzheimer's Disease Cooperative Study
    NIH U19AG010483May 1, 2015 - Nov 30, 2017
    Role: Co-Principal Investigator
    A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
    NIH R01AG030048Aug 1, 2008 - Jun 30, 2015
    Role: Principal Investigator
    Pilot Study of Huperzine A in Alzheimer's Disease
    NIH R01AG019268Sep 30, 2001 - Aug 31, 2007
    Role: Principal Investigator
    Alzheimer's Disease Cooperative Study (ADCS)
    NIH U01AG010483Jul 1, 1997 - Nov 30, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Front Neurol. 2020; 11:592302. PMID: 33551954.
      View in: PubMed   Mentions:
    2. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021 Jan 19. Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, Thipphawong J, Saad ZS, Kolb H, Rofael H, Sanga P, Romano G. PMID: 33464300.
      View in: PubMed   Mentions:    Fields:    
    3. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. J Prev Alzheimers Dis. 2021; 8(1):59-67. Papp KV, Rentz DM, Maruff P, Sun CK, Raman R, Donohue MC, Schembri A, Stark C, Yassa MA, Wessels AM, Yaari R, Holdridge KC, Aisen PS, Sperling RA. PMID: 33336226.
      View in: PubMed   Mentions: 1     Fields:    
    4. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain. 2020 Nov 30. Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, Tariot PN, Aisen PS, Vellas B, Voss T, Mahoney E, Mukai Y, Kennedy ME, Lines C, Michelson D, Egan MF. PMID: 33253354.
      View in: PubMed   Mentions:    Fields:    
    5. The search for Alzheimer disease therapeutics - same targets, better trials? Nat Rev Neurol. 2020 Nov; 16(11):597-598. Rafii MS, Aisen PS. PMID: 32963375.
      View in: PubMed   Mentions:    Fields:    
    6. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118. PMID: 33163609.
      View in: PubMed   Mentions:
    7. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimers Dement. 2020 11; 16(11):1483-1492. Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, Furtek C, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, Dupre N, Randolph C, Michelson D, Andersen SW, Shering C, Sims JR, Egan MF. PMID: 33049114.
      View in: PubMed   Mentions:    Fields:    
    8. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020 Sep 01; 77(9):1099-1109. Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. PMID: 32568367.
      View in: PubMed   Mentions: 6     Fields:    
    9. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020 Aug 10. Grill JD, Raman R, Ernstrom K, Sultzer DL, Burns JM, Donohue MC, Johnson KA, Aisen PS, Sperling RA, Karlawish J. PMID: 32777010.
      View in: PubMed   Mentions:    Fields:    
    10. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020 Nov; 91(11):1201-1209. Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, Gauthier S, Aisen PS, Vellas B. PMID: 32690803.
      View in: PubMed   Mentions: 4     Fields:    
    11. Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. Biol Psychiatry. 2020 Jul 02. PMID: 32980132.
      View in: PubMed   Mentions:    Fields:    
    12. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurol. 2020 Jun 22. Raghavan NS, Dumitrescu L, Mormino E, Mahoney ER, Lee AJ, Gao Y, Bilgel M, Goldstein D, Harrison T, Engelman CD, Saykin AJ, Whelan CD, Liu JZ, Jagust W, Albert M, Johnson SC, Yang HS, Johnson K, Aisen P, Resnick SM, Sperling R, De Jager PL, Schneider J, Bennett DA, Schrag M, Vardarajan B, Hohman TJ, Mayeux R. PMID: 32568366.
      View in: PubMed   Mentions: 2     Fields:    
    13. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. 2020 Jun 01; 77(6):735-745. Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, Siemers E, Johnson KA, Aisen PS. PMID: 32250387.
      View in: PubMed   Mentions: 12     Fields:    
    14. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimers Dement. 2020 05; 16(5):797-803. Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS. PMID: 32270600.
      View in: PubMed   Mentions:    Fields:    
    15. Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2020 Apr 06; 1-6. Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, Sabbagh M, Schneider L, Tanzi R, Tariot P, Weiner M, Touchon J, Vellas B. PMID: 32420298.
      View in: PubMed   Mentions: 2     Fields:    
    16. Neuroanatomical spread of amyloid ß and tau in Alzheimer's disease: implications for primary prevention. Brain Commun. 2020; 2(1):fcaa007. Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. PMID: 32140682.
      View in: PubMed   Mentions:
    17. Data-Driven Participant Recruitment: Findings from the Alzheimer's Disease Neuroimaging Initiative 3. J Prev Alzheimers Dis. 2020; 7(2):122-127. Barger C, Fockler J, Kwang W, Moore S, Flenniken D, Ulbricht A, Aisen P, Weiner MW. PMID: 32236401.
      View in: PubMed   Mentions:    Fields:    
    18. The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis. 2020; 7(3):146-151. Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, Sims J, Sperling RA, Vellas B. PMID: 32463066.
      View in: PubMed   Mentions: 4     Fields:    
    19. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business. J Prev Alzheimers Dis. 2020; 7(3):195-196. Aisen PS, Raman R. PMID: 32463073.
      View in: PubMed   Mentions:    Fields:    
    20. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. J Prev Alzheimers Dis. 2020; 7(4):213-218. Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G, Aisen PS, Donohue MC. PMID: 32920622.
      View in: PubMed   Mentions: 3     Fields:    
    21. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD). J Prev Alzheimers Dis. 2020; 7(4):219-225. Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, Jimenez-Maggiora GA, Sperling RA, Cummings JL, Aisen PS. PMID: 32920623.
      View in: PubMed   Mentions: 3     Fields:    
    22. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. J Prev Alzheimers Dis. 2020; 7(4):226-233. Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, Sperling RA, Cummings JL, Aisen PS. PMID: 32920624.
      View in: PubMed   Mentions: 2     Fields:    
    23. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. J Prev Alzheimers Dis. 2020; 7(4):234-241. Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS, Shaffer EJ, Sperling RA, Cummings JL, Aisen PS. PMID: 32920625.
      View in: PubMed   Mentions: 2     Fields:    
    24. Authors response to D Umbricht, letter to the editor referring Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer's Disease, 2020. J Prev Alzheimers Dis. 2020; 7(4):300. Aisen PS, Raman R. PMID: 32920636.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. J Prev Alzheimers Dis. 2020; 7(4):208-212. Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggiora GA, Rissman RA, Rafii MS, Walter S, Clanton T, Raman R. PMID: 32920621.
      View in: PubMed   Mentions: 3     Fields:    
    26. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimers Res Ther. 2019 08 07; 11(1):68. Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D. PMID: 31387606.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    27. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimers Dement. 2019 09; 15(9):1208-1217. Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, Song B, Zhu SL, Li DH, Wang HF, Tan CC, Dong Q, Tan L, Mok V, Aisen PS, Weiner MM. PMID: 31399333.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    28. Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiol Aging. 2019 10; 82:110-119. Nosheny RL, Insel PS, Mattsson N, Tosun D, Buckley S, Truran D, Schuff N, Aisen PS, Weiner MW. PMID: 31437719.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Jul 22. van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. PMID: 31329216.
      View in: PubMed   Mentions: 6     Fields:    
    30. The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:308-318. Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC. PMID: 31367671.
      View in: PubMed   Mentions:
    31. Predicting the course of Alzheimer's progression. Brain Inform. 2019 Jun 28; 6(1):6. Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC. PMID: 31254120.
      View in: PubMed   Mentions:
    32. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019 Apr 11; 380(15):1408-1420. Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D. PMID: 30970186.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    33. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med. 2019 04 11; 380(15):1483-1485. Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. PMID: 30970197.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    34. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimers Dement. 2019 05; 15(5):615-624. Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH. PMID: 30872114.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs. 2019 02; 33(2):99-106. Rafii MS, Aisen PS. PMID: 30560544.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Unsuccessful trials of therapies for Alzheimer's disease. Lancet. 2019 01 05; 393(10166):29. Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC. PMID: 30614456.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Editorial: Failure After Failure. What Next in AD Drug Development? J Prev Alzheimers Dis. 2019; 6(3):150. Aisen PS. PMID: 31062821.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2019; 6(3):157-163. Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B. PMID: 31062825.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019; 6(3):164-168. Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. PMID: 31062826.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    40. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019; 6(3):169-173. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. PMID: 31062827.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    41. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. J Prev Alzheimers Dis. 2019; 6(3):198-203. Vellas B, Bain LJ, Touchon J, Aisen PS. PMID: 31062835.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease. J Prev Alzheimers Dis. 2019; 6(4):228-231. Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F. PMID: 31686093.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    43. Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. Neuroimage Clin. 2019; 21:101574. Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG. PMID: 30553759.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2019 01; 15(1):106-152. Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. PMID: 30321505.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    45. Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. Alzheimers Dement. 2018 11; 14(11):1397-1405. Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH. PMID: 30297140.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018 09; 15(9):e1002660. Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M. PMID: 30248105.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    47. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (Amst). 2018; 10:657-668. Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. PMID: 30456292.
      View in: PubMed   Mentions:
    48. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neurodegener Dis. 2018; 18(4):173-190. Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. PMID: 30089306.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 07 01; 75(7):834-841. Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS. PMID: 29582053.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    50. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimers Dement. 2018 08; 14(8):1077-1087. Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC. PMID: 29753531.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    51. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018 05 03; 378(18):1691-1703. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. PMID: 29719179.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    52. A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:46-53. Chen YF, Ni X, Fleisher AS, Zhou W, Aisen P, Mohs R. PMID: 29955651.
      View in: PubMed   Mentions:
    53. Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2018 01 16; 90(3):145. Aisen PS. PMID: 29335309.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(3):171-174. Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B. PMID: 29972209.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease. J Prev Alzheimers Dis. 2018; 5(1):8-14. Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E. PMID: 29405226.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    56. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(2):98-102. Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, Porsteinsson A, Rosenberg P, Schneider L, Touchon J, Aisen P, Vellas B, Lyketsos C. PMID: 29616702.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2018; 5(2):103-109. PMID: 29616703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? J Nutr Health Aging. 2018; 22(8):982-998. Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S. PMID: 30272103.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    59. What We Learn from the CTAD (Clinical Trials Alzheimer's Disease) 2018. J Prev Alzheimers Dis. 2018; 5(4):214-215. Vellas B, Aisen P, Weiner M, Touchon J. PMID: 30298178.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    60. Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3. J Prev Alzheimers Dis. 2018; 5(3):184-187. Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen P. PMID: 29972211.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Elevated Brain Amyloid in Cognitively Normal Individuals-Reply. JAMA. 2017 10 10; 318(14):1393-1394. Donohue MC, Aisen PS. PMID: 29049582.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2017 Dec; 60:92-103. PMID: 28941407.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    63. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther. 2017 Aug 09; 9(1):60. PMID: 28793924.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    64. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017 06 13; 317(22):2305-2316. PMID: 28609533.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    65. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y). 2017 06; 3(2):177-188. PMID: 28758146.
      View in: PubMed   Mentions:
    66. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Med Genomics. 2017 05 24; 10(Suppl 1):29. PMID: 28589856.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    67. Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals. Brain. 2017 May 01; 140(5):1499-1512. Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW. PMID: 28334939.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    68. Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017; 27(6):1104-1114. PMID: 28402165.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    69. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 02; 88(18):1768-1775. PMID: 28381506.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    70. Randomized controlled trials in mild cognitive impairment: Sources of variability. Neurology. 2017 May 02; 88(18):1751-1758. PMID: 28381516.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    71. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017 Apr; 13(4):e1-e85. PMID: 28342697.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    72. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012. PMID: 28253478.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    73. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation. 2017 01 03; 14(1):1. PMID: 28086917.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    74. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124. PMID: 29186281.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. J Alzheimers Dis. 2017; 60(2):427-437. PMID: 28854503.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    76. Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimers Dement (N Y). 2017 Jan; 3(1):123-129. PMID: 28758145.
      View in: PubMed   Mentions:
    77. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis. 2017; 56(1):229-237. PMID: 27911294.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    78. Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism. J Prev Alzheimers Dis. 2017; 4(4):211-212. Aisen PS. PMID: 29181483.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    79. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease. J Nutr Health Aging. 2017; 21(10):1072-1074. PMID: 29188862.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2017 May; 13(5):561-571. PMID: 27931796.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    81. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016 09 20; 8:39. PMID: 27646601.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimals
    82. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 12; 48:172-181. PMID: 27710807.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    83. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016 08 12; 9 Suppl 1:30. PMID: 27535542.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 06 30; 8:25. PMID: 27358067.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    85. Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. PMID: 29067300.
      View in: PubMed   Mentions:
    86. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 06 01; 73(6):721-32. PMID: 27088965.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    87. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016 May 31; 86(22):2071-6. PMID: 27164691.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    88. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 05; 12(5):631-2. PMID: 27157073.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    89. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 05 17; 86(20):1887-96. PMID: 27164667.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    90. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. J Prev Alzheimers Dis. 2016 Jun; 3(2):114-120. PMID: 28459045.
      View in: PubMed   Mentions: 17     Fields:    
    91. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. PMID: 26998469.
      View in: PubMed   Mentions: 10     Fields:    
    92. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. PMID: 27012484.
      View in: PubMed   Mentions: 259     Fields:    Translation:HumansAnimals
    93. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimers Dement. 2016 05; 12(5):598-603. PMID: 26917500.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia. J Prev Alzheimers Dis. 2016; 3(4):185-187. Sperling R, Cummings J, Donohue M, Aisen P. PMID: 29199318.
      View in: PubMed   Mentions: 2     Fields:    
    95. JPAD Is Moving Fast. J Prev Alzheimers Dis. 2016; 3(1):3-4. Touchon J, Aisen P, Vellas B. PMID: 29214275.
      View in: PubMed   Mentions:    Fields:    
    96. Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. J Prev Alzheimers Dis. 2016; 3(3):138-144. PMID: 29205252.
      View in: PubMed   Mentions: 4     Fields:    
    97. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2016; 3(2):68-74. PMID: 29210442.
      View in: PubMed   Mentions: 11     Fields:    
    98. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis. 2015 Dec 01; 2(4):227-241. PMID: 27019841.
      View in: PubMed   Mentions: 8     Fields:    
    99. CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan; 12(1):56-61. PMID: 26416539.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    100. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. PMID: 26402088.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    101. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. PMID: 26441570.
      View in: PubMed   Mentions:
    102. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91. PMID: 26362286.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    103. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015 Oct; 138(Pt 10):3076-88. PMID: 26268530.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    104. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. PMID: 29854931.
      View in: PubMed   Mentions:
    105. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep; 14(9):926-944. PMID: 26213339.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    106. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement. 2015 Jul; 11(7):734-9. PMID: 26194309.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    107. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement. 2015 Jul; 11(7):772-91. PMID: 26194312.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    108. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015 Jul; 11(7):823-31. PMID: 26194315.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    109. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015 Jul; 11(7):865-84. PMID: 26194320.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    110. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. PMID: 26120368.
      View in: PubMed   Mentions: 10     Fields:    
    111. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. PMID: 26120369.
      View in: PubMed   Mentions: 11     Fields:    
    112. Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):36. Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS. PMID: 26064192.
      View in: PubMed   Mentions: 9     Fields:    
    113. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-120. PMID: 26073027.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    114. Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2015 Jun; 2(2):128-135. PMID: 26247004.
      View in: PubMed   Mentions: 14     Fields:    
    115. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-1429. PMID: 25960448.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    116. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May; 72(5):554-60. PMID: 25775167.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    117. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr; 72(4):446-54. PMID: 25706191.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    118. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. PMID: 26238228.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    119. Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. PMID: 25857341.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    120. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. PMID: 26000325.
      View in: PubMed   Mentions: 7     Fields:    
    121. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015 Mar; 77(3):547-52. PMID: 25559091.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    122. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. PMID: 25681451.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    123. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015; 43(3):949-55. PMID: 25125457.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    124. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):205-14. PMID: 26402769.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    125. Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. J Prev Alzheimers Dis. 2015; 2(2):82-84. PMID: 26779453.
      View in: PubMed   Mentions: 6     Fields:    
    126. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. PMID: 25537424.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    127. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. PMID: 25685141.
      View in: PubMed   Mentions:
    128. The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. PMID: 25499535.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    129. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis. 2014 Dec; 1(3):181-202. PMID: 26478889.
      View in: PubMed   Mentions: 19     Fields:    
    130. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement. 2015 Sep; 11(9):1080-9. PMID: 25449531.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    131. FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry. 2015 Oct; 20(10):1197-204. PMID: 25385369.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    132. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement. 2015 Sep; 11(9):1069-79. PMID: 25301682.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    133. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. PMID: 25341459.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    134. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. 2015 Jan; 36(1):273-82. PMID: 25175807.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    135. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70. PMID: 24886908.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    136. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Mol Psychiatry. 2015 Jul; 20(7):867-73. PMID: 25023145.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    137. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15; 83(3):253-60. PMID: 24928124.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    138. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. PMID: 24924673.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    139. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. PMID: 24828933.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460. PMID: 24716687.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    141. Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology. 2014 Apr 29; 82(17):1536-42. PMID: 24696507.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    142. Serum brain-derived neurotrophic factor and the risk for dementia. JAMA. 2014 Apr 23-30; 311(16):1684-5. PMID: 24756518.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    143. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. PMID: 24656849.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    144. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. PMID: 24648338.
      View in: PubMed   Mentions: 219     Fields:    Translation:Humans
    145. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21. PMID: 24450890.
      View in: PubMed   Mentions: 436     Fields:    Translation:HumansCTClinical Trials
    146. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014 Jan 15; 14:12. PMID: 24423155.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    147. Journal of Prevention of Alzheimer's Disease (JPAD): Building a "Fleet" Against Alzheimer's Disease. J Prev Alzheimers Dis. 2014; 1(1):2-3. PMID: 29261213.
      View in: PubMed   Mentions:    Fields:    
    148. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alzheimers Dis. 2014; 1(2):110-116. Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P. PMID: 29255837.
      View in: PubMed   Mentions:    Fields:    
    149. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. PMID: 24275164.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    150. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. PMID: 24194552.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    151. Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings. Open J Philos. 2013 Nov 01; 3(4A):24-31. PMID: 26213645.
      View in: PubMed   Mentions:
    152. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. PMID: 24164929.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    153. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 10 24; 369(17):1661. PMID: 24152267.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    154. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. PMID: 23151596.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    155. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013; 8(9):e74062. PMID: 24040166.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    156. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct; 169(10):737-43. PMID: 24016464.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    157. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep; 9(5):e111-94. PMID: 23932184.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    158. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. PMID: 23686697.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    159. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. PMID: 23883379.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansCTClinical Trials
    160. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269. PMID: 23894628.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    161. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul; 27(4):391-401. PMID: 23876113.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    162. Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Mol Psychiatry. 2013 Jul; 18(7):739. PMID: 23787478.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    163. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. PMID: 23809364.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    164. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry. 2013 Jul; 18(7):781-7. PMID: 23608917.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    165. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. PMID: 23554593.
      View in: PubMed   Mentions:
    166. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. PMID: 23694947.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    167. Association of plasma and cortical amyloid beta is modulated by APOE e4 status. Alzheimers Dement. 2014 Jan; 10(1):e9-e18. PMID: 23541187.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    168. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013 Apr; 12(4):324. PMID: 23493086.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    169. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014 Mar; 19(3):351-7. PMID: 23419831.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    170. Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc. 2013 Mar; 61(3):396-402. PMID: 23414481.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    171. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. PMID: 23567388.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    172. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. PMID: 23332364.
      View in: PubMed   Mentions: 1050     Fields:    Translation:Humans
    173. Antioxidants for Alzheimer disease-reply. JAMA Neurol. 2013 Feb; 70(2):270-1. PMID: 23400724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. PMID: 23375568.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    175. Trazodone for Behavioral Disturbance in Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. PMID: 28530913.
      View in: PubMed   Mentions: 4     Fields:    
    176. Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. PMID: 28530925.
      View in: PubMed   Mentions:    Fields:    
    177. Determinants of Length of Stay in Geropsychiatry. Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. PMID: 28530996.
      View in: PubMed   Mentions: 1     Fields:    
    178. Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging. 2013 Jan; 17(1):49-50. PMID: 23299379.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    179. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013 Jan 15; 80(3):282-8. PMID: 23255824.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    180. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012 Dec; 6(4):634-48. PMID: 22865056.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    181. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. PMID: 23139856.
      View in: PubMed   Mentions:
    182. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct; 72(4):578-86. PMID: 23109153.
      View in: PubMed   Mentions: 210     Fields:    Translation:HumansPHPublic Health
    183. Apolipoprotein E epsilon4 does not modulate amyloid-ß-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol. 2013 Mar; 34(3):505-10. PMID: 22976236.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    184. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. PMID: 22935789.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    185. Informatics and Geriatric Psychiatry. Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. Aisen PS. PMID: 28531005.
      View in: PubMed   Mentions:    Fields:    
    186. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30; 367(9):795-804. PMID: 22784036.
      View in: PubMed   Mentions: 938     Fields:    Translation:Humans
    187. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 Jul; 69(7):836-41. PMID: 22431837.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    188. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. PMID: 22409939.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    189. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. PMID: 22431834.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    190. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. PMID: 22672770.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    191. Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun; 69(6):709-13. PMID: 22529247.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    192. Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. PMID: 22573913.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    193. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012 Apr; 16(4):339-45. PMID: 22499454.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    194. Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. J Nutr Health Aging. 2012 Apr; 16(4):360-4. PMID: 22499459.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    195. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. PMID: 22393531.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    196. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar; 69(3):368-72. PMID: 22410444.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    197. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. PMID: 22354745.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    198. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". PLoS One. 2012; 7(2):e30019. PMID: 22363411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    199. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. PMID: 22343285.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    200. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10; 78(2):91-101. PMID: 22232050.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    201. Testing the right target and right drug at the right stage. Sci Transl Med. 2011 Nov 30; 3(111):111cm33. PMID: 22133718.
      View in: PubMed   Mentions: 180     Fields:    Translation:Humans
    202. Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Transl Psychiatry. 2011 Nov 15; 1:e54. PMID: 22833209.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    203. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. PMID: 22047634.
      View in: PubMed   Mentions: 207     Fields:    Translation:Humans
    204. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004. PMID: 22038908.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    205. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. PMID: 22002658.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    206. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. PMID: 21983242.
      View in: PubMed   Mentions: 7     Fields:    
    207. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011 Sep 27; 77(13):1263-71. PMID: 21917762.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    208. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol. 2011 Dec; 95(4):594-600. PMID: 21925234.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    209. Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011 Sep; 7(5):514-20. PMID: 21889115.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    210. Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011 Sep 01; 9:101. PMID: 21884605.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    211. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011 Dec; 68(12):1526-35. PMID: 21825215.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    212. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. PMID: 21810649.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    213. Factors affecting Aß plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011 Oct; 122(4):401-13. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM. PMID: 21805181.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    214. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011 Aug 09; 77(6):556-63. PMID: 21795660.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    215. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. PMID: 21744390.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    216. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PMID: 21192237.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    217. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. Vellas B, Pesce A, Robert PH, Aisen PS, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. PMID: 21784343.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    218. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66. PMID: 21670386.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    219. Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. Aisen PS. PMID: 21575868.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    220. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials. 2011 Sep; 32(5):685-93. PMID: 21554992.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    221. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):280-92. PMID: 21514248.
      View in: PubMed   Mentions: 1833     Fields:    Translation:Humans
    222. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011 Apr 19; 76(16):1389-94. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. PMID: 21502597.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    223. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain. 2011 May; 134(Pt 5):1479-92. PMID: 21478184.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    224. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. PMID: 20921876.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    225. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb; 7(1):102-11. PMID: 22291741.
      View in: PubMed   Mentions:
    226. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar; 7(2):127-32. Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S, Weiner MW, Carrillo MC, Bain LJ. PMID: 21414553.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    227. Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. PMID: 21414558.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    228. Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid. Alzheimers Dement. 2011 Mar; 7(2):133-41. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR. PMID: 21282074.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    229. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011 Jan 17; 6(1):e16259. Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. PMID: 21264226.
      View in: PubMed   Mentions: 26     Fields:    Translation:Animals
    230. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011 Jan 06; 3(1):1. PMID: 21211070.
      View in: PubMed   Mentions: 136     Fields:    
    231. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:5-16. Rammouz G, Lecanu L, Aisen P, Papadopoulos V. PMID: 21335661.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    232. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. PMID: 21178097.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    233. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. PMID: 21130138.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    234. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011 Jan 04; 76(1):69-79. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. PMID: 21123754.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    235. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 03; 304(17):1903-11. PMID: 21045096.
      View in: PubMed   Mentions: 181     Fields:    Translation:Humans
    236. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010 Nov; 6(6):482-93. PMID: 21044778.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    237. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010 Nov 30; 75(22):1976-81. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR, Aisen PS, Petersen RC, Weiner MW. PMID: 20980669.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    238. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov; 133(11):3336-48. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS. PMID: 20935035.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    239. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012 May; 33(5):845-55. Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR, Weiner MW. PMID: 20855131.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    240. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 Sep; 6(5):412-9. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS. PMID: 20813342.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    241. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010 Jul 13; 75(2):143-51. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. PMID: 20625167.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    242. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM. PMID: 20683184.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    243. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010 Jul 20; 75(3):230-8. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ. PMID: 20592257.
      View in: PubMed   Mentions: 214     Fields:    Translation:Humans
    244. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. PMID: 20538372.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    245. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010 Aug; 31(8):1340-54. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW. PMID: 20570401.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    246. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Curr Gerontol Geriatr Res. 2010; 510614. Tractenberg RE, Fillenbaum G, Aisen PS, Liebke DE, Yumoto F, Kuchibhatla MN. PMID: 20585350.
      View in: PubMed   Mentions:
    247. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May; 6(3):202-11.e7. Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M. PMID: 20451868.
      View in: PubMed   Mentions: 167     Fields:    Translation:Humans
    248. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 May; 6(3):230-8. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, Jagust W, Toga AW, Lee VM, Shaw LM. PMID: 20451871.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    249. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010 May; 6(3):239-46. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW. PMID: 20451872.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    250. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. PMID: 20143386.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    251. Therapeutics for cognitive aging. Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM. PMID: 20392284.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    252. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. Edland SD, Emond JA, Aisen PS, Petersen RC. PMID: 20505433.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    253. Early Alzheimer's trials: new developments. J Nutr Health Aging. 2010 Apr; 14(4):293. Vellas B, Aisen PS. PMID: 20305997.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    254. Pre-dementia Alzheimer's trials: overview. J Nutr Health Aging. 2010 Apr; 14(4):294. Aisen PS. PMID: 20305998.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    255. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. PMID: 20298968.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    256. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010 Mar; 67(3):308-16. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR. PMID: 20373342.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    257. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan; 9(1):119-28. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. PMID: 20083042.
      View in: PubMed   Mentions: 1280     Fields:    Translation:HumansCells
    258. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19; 74(3):201-9. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. PMID: 20042704.
      View in: PubMed   Mentions: 437     Fields:    Translation:Humans
    259. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med. 2009 Nov 18; 1(7):7ra17. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC. PMID: 20368182.
      View in: PubMed   Mentions: 55     Fields:    Translation:Animals
    260. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010 Jun; 223(2):334-46. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. PMID: 19815015.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    261. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen PS, Tariot PN, Quinn JF. PMID: 19571733.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    262. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. PMID: 19571732.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    263. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009 Jul 09; 1(1):2. Aisen PS. PMID: 19674435.
      View in: PubMed   Mentions: 21     Fields:    
    264. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. Tariot PN, Aisen PS. PMID: 19573485.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    265. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009 Jun; 13(6):550-7. Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J. PMID: 19536424.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    266. Interpreting biomarker data in therapeutic trials. J Nutr Health Aging. 2009 Apr; 13(4):337-8. Aisen PS. PMID: 19300871.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    267. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J Nutr Health Aging. 2009 Apr; 13(4):370-2. Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J. PMID: 19300884.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    268. The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009 Apr; 6(2):126-32. Vozdolska R, Sano M, Aisen P, Edland SD. PMID: 19342464.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    269. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr; 65(4):403-13. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. PMID: 19296504.
      View in: PubMed   Mentions: 797     Fields:    Translation:HumansCells
    270. Agreement in cognitive and clinical assessments in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(4):344-52. Tractenberg RE, Aisen PS. PMID: 19293567.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    271. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. Aisen PS. PMID: 19328440.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    272. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. PMID: 19328434.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    273. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. Rafii MS, Aisen PS. PMID: 19228370.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    274. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009; 16(2):235-70. Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. PMID: 19221415.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsPHPublic Health
    275. Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol. 2009; 21(1):129-36. Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. PMID: 19847051.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    276. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci Lett. 2009 Jan 23; 450(1):51-5. Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y. PMID: 19022346.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    277. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. PMID: 19066433.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    278. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. PMID: 18854539.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    279. Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. Aisen PS. PMID: 18955961.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    280. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug; 65(8):1031-8. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. PMID: 18695053.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCTClinical Trials
    281. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. PMID: 18640457.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    282. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. Aisen PS. PMID: 18505976.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    283. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen PS. PMID: 18572153.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    284. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. PMID: 18631960.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    285. Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. Aisen PS. PMID: 18450518.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    286. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008 Jun 24; 1216:92-103. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. PMID: 18486110.
      View in: PubMed   Mentions: 95     Fields:    Translation:Animals
    287. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett. 2008 Apr 25; 435(3):186-9. Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen PS, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. PMID: 18343582.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    288. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiol Aging. 2009 Aug; 30(8):1327-8. Tractenberg RE, Aisen PS, Hancock GR, Rebeck GW. PMID: 18083276.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    289. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. Little JT, Walsh S, Aisen PS. PMID: 18230054.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    290. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008 Feb; 5(1):73-82. Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. PMID: 18288935.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    291. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. PMID: 18199809.
      View in: PubMed   Mentions: 78     Fields:    Translation:AnimalsCells
    292. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3):191-9. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, Thal LJ. PMID: 18195264.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    293. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. Aisen PS. PMID: 18068519.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    294. Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. Aisen PS. PMID: 18631999.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    295. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. Aisen PS. PMID: 18317241.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    296. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007 Nov; 26(9):2458-68. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. PMID: 17970733.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    297. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006."--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. Aisen PS. PMID: 19595967.
      View in: PubMed   Mentions:    Fields:    
    298. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep; 4(4):473-8. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. PMID: 17908052.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    299. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 2007 Feb 12; 18(3):293-6. Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. PMID: 17314674.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    300. A simple method to rule out dementia with temporal orientation. Alzheimers Dement. 2007 Jan; 3(1):28-32. Tractenberg RE, Weiner MF, Aisen PS, Kaye JA, Fuh JL. PMID: 19595914.
      View in: PubMed   Mentions:    Fields:    
    301. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007; 31(2):165-70. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. PMID: 17478890.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    302. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006 Dec; 99(6):1555-63. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. PMID: 17083447.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    303. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006 Nov 28; 67(10):1757-63. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. PMID: 17082468.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCellsCTClinical Trials
    304. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. Walsh SP, Raman R, Jones KB, Aisen PS. PMID: 17135810.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    305. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. PMID: 17135805.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    306. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers Dement. 2006 Oct; 2(4):272-4. Aisen PS. PMID: 19595898.
      View in: PubMed   Mentions: 5     Fields:    
    307. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. PMID: 19595904.
      View in: PubMed   Mentions: 8     Fields:    
    308. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers Dement. 2006 Jul; 2(3):153-4. Aisen PS. PMID: 19595875.
      View in: PubMed   Mentions: 2     Fields:    
    309. In vivo protein transduction to the CNS. Neuroscience. 2006; 139(3):1061-7. Loftus LT, Li HF, Gray AJ, Hirata-Fukae C, Stoica BA, Futami J, Yamada H, Aisen PS, Matsuoka Y. PMID: 16529872.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    310. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. Aisen PS. PMID: 16932488.
      View in: PubMed   Mentions:    Fields:    
    311. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. PMID: 16256090.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    312. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. Tractenberg RE, Aisen PS, Chuang YL. PMID: 16136848.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    313. An Abeta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res. 2005 Apr; 2(2):265-8. Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. PMID: 15974928.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    314. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. Aisen PS. PMID: 16033023.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    315. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005; 11(4):353-68. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. PMID: 16614735.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimals
    316. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. Aisen PS. PMID: 16332141.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    317. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 2005; 24(1-2):110-6. Tractenberg RE, Weinstein M, Weiner MF, Aisen PS, Fuh JL, Goldman N, Chuang YL. PMID: 15492486.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    318. Inflammatory processes and Alzheimer's disease. Expert Rev Neurother. 2004 Sep; 4(5):793-8. Walsh S, Aisen PS. PMID: 15853506.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    319. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. PMID: 15184044.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    320. Georgetown University School of Medicine. Acad Med. 2004 Jul; 79(7 Suppl):S45-50. Saunders PA, Aisen PS. PMID: 15240216.
      View in: PubMed   Mentions:    Fields:    
    321. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. PMID: 14732621.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansCTClinical Trials
    322. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol. 2003 Jul; 250(7):788-92. van Gool WA, Aisen PS, Eikelenboom P. PMID: 12883918.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    323. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 04; 289(21):2819-26. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. PMID: 12783912.
      View in: PubMed   Mentions: 264     Fields:    Translation:HumansCTClinical Trials
    324. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. PMID: 12742818.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    325. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. PMID: 12611755.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    326. Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology. 2003 Jan; 28(1):113-20. Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ. PMID: 12445840.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    327. Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid. J Clin Lab Anal. 2003; 17(1):18-21. Mehta PD, Patrick BA, Pirttila T, Coyle PK, Aisen PS. PMID: 12526018.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    328. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep; 1(5):279-84. Aisen PS. PMID: 12849425.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    329. Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. Aisen PS. PMID: 12169220.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    330. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002 May-Jun; 23(3):327-34. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS, Pasinetti GM. PMID: 11959394.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    331. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002 Apr 09; 58(7):1050-4. Aisen PS, Schmeidler J, Pasinetti GM. PMID: 11940691.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    332. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. Aisen PS. PMID: 11992749.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    333. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 2002 Feb; 103(2):157-62. Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM. PMID: 11810182.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    334. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001 Oct; 33(10):940-59. Aisen P, Enns C, Wessling-Resnick M. PMID: 11470229.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    335. Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun. 2001 Sep; 69(9):5760-7. Gómez BL, Nosanchuk JD, Díez S, Youngchim S, Aisen P, Cano LE, Restrepo A, Casadevall A, Hamilton AJ. PMID: 11500453.
      View in: PubMed   Mentions: 39     Fields:    Translation:Animals
    336. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001 Apr-Jun; 15(2):96-101. Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M. PMID: 11403336.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    337. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):487-92. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Mohs RC, Aisen PS, Pasinetti GM. PMID: 11255454.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    338. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett. 2001 Feb 09; 298(3):191-4. Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, Czernik A, Yemul S, Aisen PS, Mohs R, Pasinetti GM. PMID: 11165439.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    339. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001; 19(1 Suppl 22):S7-11. Mukherjee P, Rachita C, Aisen PS, Pasinetti GM. PMID: 11296547.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    340. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis Assoc Disord. 2000 Oct-Dec; 14(4):228-30. Hull M, Pasinetti GM, Aisen PS. PMID: 11186601.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    341. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000 Aug; 57(8):1153-60. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. PMID: 10927795.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    342. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 2000 Jul 25; 55(2):323. Ho L, Luterman JD, Aisen PS, Pasinetti GM, Montine TJ, Morrow JD. PMID: 10908926.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    343. Anti-inflammatory therapy for Alzheimer's disease. Neurobiol Aging. 2000 May-Jun; 21(3):447-8; discussion 451-3. Aisen PS. PMID: 10858592.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    344. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. PMID: 10680787.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    345. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand Suppl. 2000; 176:85-9. Aisen PS. PMID: 11261810.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    346. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000 Jan; 57(1):100-5. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. PMID: 10634455.
      View in: PubMed   Mentions: 158     Fields:    Translation:Humans
    347. Increased levels of tau-like protein in patients with Down syndrome. Neurosci Lett. 1999 Nov 19; 275(3):159-62. Mehta PD, Patrick BA, Dalton AJ, Aisen PS, Emmerling ME, Sersen EA, Wisniewski HM. PMID: 10580699.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    348. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999 Sep; 155(3):995-1004. Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM. PMID: 10487857.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    349. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999 Aug 01; 57(3):295-303. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. PMID: 10412020.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    350. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999 Jun 01; 73(3):303-11. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. PMID: 10321830.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    351. Iron metabolism. Curr Opin Chem Biol. 1999 Apr; 3(2):200-6. Aisen P, Wessling-Resnick M, Leibold EA. PMID: 10226041.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    352. HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. J Neurol Sci. 1998 Nov 26; 161(1):66-9. Aisen PS, Luddy A, Durner M, Reinhard JF, Pasinetti GM. PMID: 9879683.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    353. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 1998 Nov; 87(2):319-24. Pasinetti GM, Aisen PS. PMID: 9740394.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCells
    354. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol. 1998 Aug 14; 89(1-2):142-9. Ho L, Osaka H, Aisen PS, Pasinetti GM. PMID: 9726836.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    355. Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. Am J Psychiatry. 1998 May; 155(5):698-700. Gabriel SM, Marin DB, Aisen PS, Lantz M, Altstiel LD, Davis KL, Mohs RC. PMID: 9585727.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    356. Glucocorticoids in Alzheimer's disease. The story so far. Drugs Aging. 1998 Jan; 12(1):1-6. Aisen PS, Pasinetti GM. PMID: 9467682.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    357. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst. 1998; 35:585-631. Aisen P. PMID: 9444770.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    358. A kinetically active site in the C-lobe of human transferrin. Biochemistry. 1997 Sep 09; 36(36):11036-43. Zak O, Tam B, MacGillivray RT, Aisen P. PMID: 9283096.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    359. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 1997 May; 48(5 Suppl 6):S35-41. Aisen PS, Davis KL. PMID: 9153159.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    360. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol. 1997 Apr; 144(2):339-49. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. PMID: 9168834.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    361. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 1997 Mar; 12(3):319-22. Lawlor BA, Aisen PS, Green C, Fine E, Schmeïdler J. PMID: 9152715.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    362. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 1997; 43(1-2):143-9. Aisen PS. PMID: 8996836.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    363. Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun. 1996 Jul; 64(7):2420-4. Wang Y, Aisen P, Casadevall A. PMID: 8698461.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    364. A pilot study of prednisone in Alzheimer's disease. Dementia. 1996 Jul-Aug; 7(4):201-6. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL. PMID: 8835883.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    365. IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. Brain Res. 1996 Jun 03; 723(1-2):231-4. Fagarasan MO, Aisen PS. PMID: 8813406.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    366. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology. 1996 Jun; 23(6):1512-20. Trinder D, Zak O, Aisen P. PMID: 8675172.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    367. Inflammation and Alzheimer disease. Mol Chem Neuropathol. 1996 May-Aug; 28(1-3):83-8. Aisen PS. PMID: 8871945.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    368. Antinuclear antibodies in multiple sclerosis. Neurology. 1995 Dec; 45(12):2299-300;author reply 2300-1. Aisen ML, Aisen PS. PMID: 8848220.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    369. Iron release from recombinant N-lobe and mutants of human transferrin. Biochemistry. 1995 Nov 07; 34(44):14428-34. Zak O, Aisen P, Crawley JB, Joannou CL, Patel KJ, Rafiq M, Evans RW. PMID: 7578047.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    370. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun. 1995 Aug; 63(8):3131-6. Wang Y, Aisen P, Casadevall A. PMID: 7622240.
      View in: PubMed   Mentions: 137     Fields:    Translation:AnimalsCells
    371. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6. Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. PMID: 7951680.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    372. Shoulder-hand syndrome in cervical spinal cord injury. Paraplegia. 1994 Sep; 32(9):588-92. Aisen PS, Aisen ML. PMID: 7527910.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    373. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994 Aug; 151(8):1105-13. Aisen PS, Davis KL. PMID: 7518651.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    374. Primary receptor-recognition site of human transferrin is in the C-terminal lobe. J Biol Chem. 1994 Mar 11; 269(10):7110-4. Zak O, Trinder D, Aisen P. PMID: 8125919.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    375. The transferrin receptor and the release of iron from transferrin. Adv Exp Med Biol. 1994; 356:31-40. Aisen P. PMID: 7887237.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    376. The anion requirement for iron release from transferrin is preserved in the receptor-transferrin complex. Biochemistry. 1993 Aug 17; 32(32):8162-7. Egan TJ, Zak O, Aisen P. PMID: 8347616.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    377. Continuous wave electron nuclear double resonance spectroscopy. Methods Enzymol. 1993; 227:190-231. Bender CJ, Aisen P. PMID: 8255226.
      View in: PubMed   Mentions:    Fields:    
    378. Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line. Am J Hematol. 1993 Jan; 42(1):74-80. Sasaki K, Zak O, Aisen P. PMID: 8380064.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    379. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Schmeidler J, Davis KL. PMID: 8347333.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    380. Catalysis of the Haber-Weiss reaction by iron-diethylenetriaminepentaacetate. J Inorg Biochem. 1992 Dec; 48(4):241-9. Egan TJ, Barthakur SR, Aisen P. PMID: 1336036.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    381. Neuroleptic malignant syndrome induced by low-dose haloperidol. Am J Psychiatry. 1992 Jun; 149(6):844. Aisen PS, Lawlor BA. PMID: 1590507.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    382. Receptor-induced switch in site-site cooperativity during iron release by transferrin. Biochemistry. 1992 Apr 28; 31(16):3963-7. Bali PK, Aisen P. PMID: 1567848.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    383. Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin. Ann Neurol. 1992; 32 Suppl:S62-8. Aisen P. PMID: 1510382.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    384. GPSYCH: Clinical management software for a Geropsychiatry Division. Proc Annu Symp Comput Appl Med Care. 1992; 322-6. Aisen PS, Lawlor BA. PMID: 1482890.
      View in: PubMed   Mentions:    Fields:    
    385. Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites. Biochemistry. 1991 Oct 15; 30(41):9947-52. Bali PK, Aisen P. PMID: 1911786.
      View in: PubMed   Mentions: 27     Fields:    Translation:Cells
    386. A new role for the transferrin receptor in the release of iron from transferrin. Biochemistry. 1991 Jan 15; 30(2):324-8. Bali PK, Zak O, Aisen P. PMID: 1988034.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    387. Ferritin receptors and the role of ferritin in iron transport. Targeted Diagn Ther. 1991; 4:339-54. Aisen P. PMID: 1665721.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    388. Medical evaluation of the elderly psychiatric patient. Mt Sinai J Med. 1991 Jan; 58(1):85-90. Aisen PS. PMID: 2023594.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    389. Evidence for functional differences between the two sites of rabbit transferrin: effects of serum and carbon dioxide. Biochim Biophys Acta. 1990 Apr 09; 1052(1):24-8. Zak O, Aisen P. PMID: 2108730.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    390. Release of iron from diferric transferrin in the presence of rat liver plasma membranes: no evidence of a plasma membrane diferric transferrin reductase. Biochim Biophys Acta. 1990 Apr 09; 1052(1):29-35. Thorstensen K, Aisen P. PMID: 2157501.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    391. Iron toxicosis. Int Rev Exp Pathol. 1990; 31:1-46. Aisen P, Cohen G, Kang JO. PMID: 2292470.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    392. Subcellular localization of ferritin and iron taken up by rat hepatocytes. Biochem J. 1989 Sep 01; 262(2):685-8. Sibille JC, Ciriolo M, Kondo H, Crichton RR, Aisen P. PMID: 2803277.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    393. Hypochondriasis in the elderly depressed. J Am Geriatr Soc. 1989 Jun; 37(6):507-10. Kramer-Ginsberg E, Greenwald BS, Aisen PS, Brod-Miller C. PMID: 2715557.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    394. Pathways in the binding and uptake of ferritin by hepatocytes. Biochim Biophys Acta. 1989 Mar 28; 1011(1):40-5. Osterloh K, Aisen P. PMID: 2538147.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    395. Uptake of ferritin and iron bound to ferritin by rat hepatocytes: modulation by apotransferrin, iron chelators and chloroquine. Biochim Biophys Acta. 1989 Feb 09; 1010(2):204-9. Sibille JC, Kondo H, Aisen P. PMID: 2912502.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    396. Occult aspiration of a nut in an elderly patient: a case report. Am J Forensic Med Pathol. 1988 Jun; 9(2):163-5. Pervez NK, Aisen PS, Bleiweiss IJ, Brady B, Winters S. PMID: 3381798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    397. The binding of molybdate to uteroferrin. Hyperfine interactions of the binuclear center with 95Mo, 1H, and 2H. J Biol Chem. 1988 Apr 25; 263(12):5757-63. Doi K, McCracken J, Peisach J, Aisen P. PMID: 2833515.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    398. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology. 1988 Mar-Apr; 8(2):296-301. Sibille JC, Kondo H, Aisen P. PMID: 3356411.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    399. Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin. Biochemistry. 1988 Feb 09; 27(3):1075-80. Zak O, Aisen P. PMID: 2835077.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    400. Iron metabolism in isolated liver cells. Ann N Y Acad Sci. 1988; 526:93-100. Aisen P. PMID: 2839075.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    401. Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology. 1988 Jan-Feb; 8(1):32-8. Kondo H, Saito K, Grasso JP, Aisen P. PMID: 3338718.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    402. Interaction of transferrin with iron-loaded rat peritoneal macrophages. Br J Haematol. 1986 Feb; 62(2):275-86. Saito K, Nishisato T, Grasso JA, Aisen P. PMID: 3947549.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    403. The novel "g' = 1.74" EPR spectrum of pink and purple uteroferrin. J Biol Chem. 1980 Dec 10; 255(23):11204-9. Antanaitis BC, Aisen P, Lilienthal HR, Roberts RM, Bazer FW. PMID: 6254963.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    404. EPR and other studies of the anion-binding sites of transferrin. Ann N Y Acad Sci. 1973 Dec 31; 222:337-46. Aisen P, Pinkowitz RA, Leibman A. PMID: 4361858.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    405. Citrate-mediated exchange of FE3+ among tranferrin molecules. Biochem Biophys Res Commun. 1968 Jul 26; 32(2):220-6. Aisen P. PMID: 5672138.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    406. The stability constants of the Fe3+ conalbumin complexes. Biochem Biophys Res Commun. 1968 Feb 26; 30(4):407-13. Aisen P, Leibman A. PMID: 5637046.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    Paul's Networks
    Concepts (829)
    Derived automatically from this person's publications.
    _
    Co-Authors (83)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _